Walbrook PR appointed by Lipoxen plc

 

TIDMLPX 
 
RNS Number : 2963W 
Lipoxen PLC 
17 November 2010 
 

 
      Walbrook PR appointed by Lipoxen plc as financial PR and IR advisor 
 
 
Lipoxen (AIM: LPX.L), ('Lipoxen' or 'the Company') a bio-pharmaceutical company 
specialising in the development of high-value differentiated biologicals, 
vaccines and siRNA delivery, is pleased to announce the appointment of Walbrook 
PR Ltd as its financial PR and IR advisor. 
 
For further information, please contact: 
Enquiries 
+-----------------------------------+-------------------------------+ 
| Lipoxen plc                       |           [phone] | 
+-----------------------------------+-------------------------------+ 
| M. Scott Maguire, Chief Executive |                               | 
| Officer                           |                               | 
+-----------------------------------+-------------------------------+ 
|                                   |                               | 
+-----------------------------------+-------------------------------+ 
| Singer Capital Markets (nominated |           [phone] | 
| adviser)                          |                               | 
+-----------------------------------+-------------------------------+ 
| Jeff Keating / Claes Spång        |                               | 
+-----------------------------------+-------------------------------+ 
|                                   |                               | 
+-----------------------------------+-------------------------------+ 
| Walbrook PR Ltd                   |           [phone] | 
+-----------------------------------+-------------------------------+ 
| Paul McManus (Media Relations)    |   [e-mail] | 
+-----------------------------------+-------------------------------+ 
| Paul Cornelius (Investor          | [e-mail] | 
| Relations)                        |                               | 
+-----------------------------------+-------------------------------+ 
|                                   |                               | 
+-----------------------------------+-------------------------------+ 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines.  Lipoxen has three proprietary patented 
technology platforms: 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
Lipoxen has multiple drug and vaccine programmes in development.  Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and an exclusive license deal with 
Baxter Healthcare for blood coagulation drugs. 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities.  Lipoxen currently has commercial agreements with some 
of the world's leading biotechnology and pharmaceutical companies including 
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and 
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and 
management led the GBP2.9 million fundraising that the Company announced in May 
2009. This fundraising was followed up by a GBP1.2 million placing in April 2010 
which was led by the Company's management team. 
 
Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock 
Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 STRGMMMMNVFGGZM